194 related articles for article (PubMed ID: 35546370)
1. Fracture risk associated with glucocorticoid-induced osteoporosis in Japan.
Soen S; Kaku M; Okubo N; Onishi Y; Saito K; Kobayashi M
J Bone Miner Metab; 2022 Jul; 40(4):636-647. PubMed ID: 35546370
[TBL] [Abstract][Full Text] [Related]
2. Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan.
Soen S; Kaku M; Okubo N; Touzeni S; Saito K; Kobayashi M
J Bone Miner Metab; 2021 Nov; 39(6):1019-1030. PubMed ID: 34125296
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid-induced osteoporosis in Malaysia.
Mohd-Tahir NA; Thomas P; Mohamed-Said MS; Makmor-Bakry M; Li SC
Int J Rheum Dis; 2018 Mar; 21(3):647-655. PubMed ID: 29105349
[TBL] [Abstract][Full Text] [Related]
4. Risk of fracture in women with glucocorticoid requiring diseases is independent from glucocorticoid use: An analysis on a nation-wide database.
Adami G; Gatti D; Rossini M; Giollo A; Gatti M; Bertoldo F; Bertoldo E; Mudano AS; Saag KG; Viapiana O; Fassio A
Bone; 2024 Feb; 179():116958. PubMed ID: 37949390
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid-induced Osteoporosis.
Whittier X; Saag KG
Rheum Dis Clin North Am; 2016 Feb; 42(1):177-89, x. PubMed ID: 26611558
[TBL] [Abstract][Full Text] [Related]
7. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis].
Hayakawa N; Suzuki A
Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371
[TBL] [Abstract][Full Text] [Related]
8. Effect of bisphosphonates or teriparatide on mechanical complications after posterior instrumented fusion for osteoporotic vertebral fracture: a multi-center retrospective study.
Kawabata A; Yoshii T; Hirai T; Ushio S; Kaito T; Yamashita T; Fujiwara H; Nagamoto Y; Matsuoka Y; Suzuki H; Nishimura H; Terai H; Tamai K; Tagami A; Yamada S; Adachi S; Watanabe K; Katsumi K; Ohashi M; Shibuya Y; Harimaya K; Kawaguchi K; Yokoyama N; Oishi H; Doi T; Kimura A; Inoue H; Inoue G; Miyagi M; Saito W; Nakano A; Sakai D; Nukaga T; Ikegami S; Shimizu M; Futatsugi T; Ohtori S; Furuya T; Orita S; Imagama S; Ando K; Kobayashi K; Kiyasu K; Murakami H; Yoshioka K; Seki S; Hongo M; Kakutani K; Yurube T; Aoki Y; Oshima M; Takahata M; Iwata A; Endo H; Abe T; Tsukanishi T; Nakanishi K; Watanabe K; Hikata T; Suzuki S; Isogai N; Okada E; Funao H; Ueda S; Shiono Y; Nojiri K; Hosogane N; Ishii K
BMC Musculoskelet Disord; 2020 Jul; 21(1):420. PubMed ID: 32611386
[TBL] [Abstract][Full Text] [Related]
9. Guideline adherence by physicians for management of glucocorticoid-induced osteoporosis in Japan: a nationwide health insurance claims database study.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Osteoporos Int; 2022 May; 33(5):1097-1108. PubMed ID: 35022812
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study.
Rossini M; Viapiana O; Vitiello M; Malavolta N; La Montagna G; Maddali Bongi S; Di Munno O; Nuti R; Manzini CU; Ferri C; Bogliolo L; Mathieu A; Cantatore F; Del Puente A; Muratore M; Grassi W; Frediani B; Saviola G; Delvino P; Mirone L; Ferraccioli G; Tripi G; Piazza I; Gatti D
Reumatismo; 2017 May; 69(1):30-39. PubMed ID: 28535619
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
[TBL] [Abstract][Full Text] [Related]
12. Initiation of anti-osteoporotic drugs in high-risk female patients starting glucocorticoid treatment: a population study in Norway.
Apalset EM; Lunde A; Hoff M; Ehrenstein V; Tell GS
Arch Osteoporos; 2020 Aug; 15(1):121. PubMed ID: 32757143
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of anti-osteoporosis medications for the prevention of incident hip and clinical vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2023 Jan; 166():116605. PubMed ID: 36347433
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis.
Ma CC; Xu SQ; Gong X; Wu Y; Qi S; Liu W; Xu JH
Arch Osteoporos; 2017 Dec; 12(1):33. PubMed ID: 28374332
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of 18 anti-osteoporotic drugs in the treatment of patients with osteoporosis caused by glucocorticoid: A network meta-analysis of randomized controlled trials.
Liu Z; Zhang M; Shen Z; Ke J; Zhang D; Yin F
PLoS One; 2020; 15(12):e0243851. PubMed ID: 33326444
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
Murphy DR; Smolen LJ; Klein TM; Klein RW
BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
[TBL] [Abstract][Full Text] [Related]
17. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures.
Gourlay M; Franceschini N; Sheyn Y
Clin Rheumatol; 2007 Feb; 26(2):144-53. PubMed ID: 16670825
[TBL] [Abstract][Full Text] [Related]
18. Delayed initiation of anti-osteoporosis medications increases subsequent hip and vertebral fractures in patients on long-term glucocorticoid therapy: A nationwide health insurance claims database study in Japan.
Iki M; Fujimori K; Nakatoh S; Tamaki J; Ishii S; Okimoto N; Kamiya K; Ogawa S
Bone; 2022 Jul; 160():116396. PubMed ID: 35351673
[TBL] [Abstract][Full Text] [Related]
19. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan.
Moriwaki K; Fukuda H
Osteoporos Int; 2019 Feb; 30(2):299-310. PubMed ID: 30610244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
